75 related articles for article (PubMed ID: 20005198)
21. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
[TBL] [Abstract][Full Text] [Related]
22. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I.
Arnout J; Meijer P; Vermylen J
Thromb Haemost; 1999 Jun; 81(6):929-34. PubMed ID: 10404770
[TBL] [Abstract][Full Text] [Related]
23. Adsorption of vitamin K-dependent blood coagulation proteins to spread phospholipid monolayers as determined from combined measurements of the surface pressure and surface protein concentration.
Ellison EH; Castellino FJ
Biochemistry; 1998 Jun; 37(22):7997-8003. PubMed ID: 9609692
[TBL] [Abstract][Full Text] [Related]
24. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls.
Triplett DA
J Autoimmun; 2000 Sep; 15(2):173-8. PubMed ID: 10968905
[TBL] [Abstract][Full Text] [Related]
25. Comparison of test methods for the lupus anticoagulant: international survey on lupus anticoagulants-I (ISLA-1).
Exner T; Triplett DA; Taberner DA; Howard MA; Harris EN
Thromb Haemost; 1990 Nov; 64(3):478-84. PubMed ID: 2128977
[TBL] [Abstract][Full Text] [Related]
26. The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome.
Arnout J
Verh K Acad Geneeskd Belg; 2000; 62(5):353-72. PubMed ID: 11144685
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of recently described tests for detection of the lupus anticoagulant.
Forastiero RR; Cerrato GS; Carreras LO
Thromb Haemost; 1994 Nov; 72(5):728-33. PubMed ID: 7900080
[TBL] [Abstract][Full Text] [Related]
28. Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids.
Pengo V; Balestrieri G; Tincani A; Spatola L; Biasiolo A; Brocco T
Thromb Haemost; 1997 Jan; 77(1):123-6. PubMed ID: 9031461
[TBL] [Abstract][Full Text] [Related]
29. Probing the interaction of coagulation factors with phospholipid vesicle surfaces by surface plasma resonance.
Wikström A; Deinum J
Anal Biochem; 2007 Mar; 362(1):98-107. PubMed ID: 17239338
[TBL] [Abstract][Full Text] [Related]
30. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests.
Galli M; Dlott J; Norbis F; Ruggeri L; Cler L; Triplett DA; Barbui T
Thromb Haemost; 2000 Dec; 84(6):1012-6. PubMed ID: 11154107
[TBL] [Abstract][Full Text] [Related]
31. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies.
Pengo V; Biasiolo A; Rampazzo P; Brocco T
Thromb Haemost; 1999 Feb; 81(2):256-8. PubMed ID: 10064002
[TBL] [Abstract][Full Text] [Related]
32. Interactions of vitamin K-dependent proteins with calcium ions and phospholipid membranes.
Nelsestuen GL
Fed Proc; 1978 Oct; 37(12):2621-5. PubMed ID: 700172
[TBL] [Abstract][Full Text] [Related]
33. Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites.
Shi J; Gilbert GE
Blood; 2003 Apr; 101(7):2628-36. PubMed ID: 12517809
[TBL] [Abstract][Full Text] [Related]
34. Immunological specificity and mechanism of action of IgG lupus anticoagulants.
Pengo V; Thiagarajan P; Shapiro SS; Heine MJ
Blood; 1987 Jul; 70(1):69-76. PubMed ID: 3109526
[TBL] [Abstract][Full Text] [Related]
35. Anticoagulant Effect of Sugammadex: Just an In Vitro Artifact.
Dirkmann D; Britten MW; Pauling H; Weidle J; Volbracht L; Görlinger K; Peters J
Anesthesiology; 2016 Jun; 124(6):1277-85. PubMed ID: 26950705
[TBL] [Abstract][Full Text] [Related]
36. The dilute Russell's viper venom time.
Radhakrishnan K
Methods Mol Biol; 2013; 992():341-8. PubMed ID: 23546726
[TBL] [Abstract][Full Text] [Related]
37. A phospholipase A2 with anticoagulant activity. II. Inhibition of the phospholiped activity in coagulation.
Boffa MC; Boffa GA
Biochim Biophys Acta; 1976 May; 429(3):839-52. PubMed ID: 5143
[TBL] [Abstract][Full Text] [Related]
38. Phospholipid-binding properties of calphobindin-II(annexin VI), anticoagulant protein from human placenta.
Yoshizaki H; Hashimoto Y; Arai K; Ohkuchi M; Shiratsuchi M; Shidara Y; Maki M
Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2617-21. PubMed ID: 1839615
[TBL] [Abstract][Full Text] [Related]
39. Studies on phospholipids in the action of a lupus coagulation inhibitor.
Exner T; Rickard KA; Kronenberg H
Pathology; 1975 Oct; 7(4):319-28. PubMed ID: 1223721
[TBL] [Abstract][Full Text] [Related]
40. Interaction of heparin with two synthetic peptides that neutralize the anticoagulant activity of heparin.
Wang J; Rabenstein DL
Biochemistry; 2006 Dec; 45(51):15740-7. PubMed ID: 17176096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
